Study Design and Rationale for the TETON-PPF Phase 3, Randomized, Controlled Clinical Trial of Inhaled Treprostinil in the Treatment of Progressive Pulmonary FibrosisTake-Home Points

Study Design and Rationale for the TETON-PPF Phase 3, Randomized, Controlled Clinical Trial of Inhaled Treprostinil in the Treatment of Progressive Pulmonary FibrosisTake-Home Points

Background: Progressive pulmonary fibrosis (PPF) affects a group of patients with various underlying interstitial lung diseases (ILDs) who develop progressive fibrosis and exhibit a similar disease course to patients with idiopathic pulmonary fibrosis (IPF). In PPF, fibrosis becomes self-sustaining...

Full description

Saved in:
Bibliographic Details
Main Authors: Steven D. Nathan, MD, Juergen Behr, MD, Vincent Cottin, MD, Lisa Lancaster, MD, Peter Smith, PharmD, CQ Deng, PhD, Natalie Breytenbach, PharmD, Heidi Bell, MD, Leigh Peterson, PhD, Kevin R. Flaherty, MD
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:CHEST Pulmonary
Subjects:
clinical trial
interstitial lung disease
phase 3
progressive pulmonary fibrosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2949789224000904
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2949789224000904

Similar Items